c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
### c-Met/HGFR Inhibitors & Activators

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2-Phospho-L-ascorbic acid trisodium salt</strong></td>
<td>HY-107837</td>
<td>2-Phospho-L-ascorbic acid trisodium salt acts as an antioxidant and a stimulator of hepatocyte growth factor (HGF) production.</td>
</tr>
<tr>
<td><strong>AMG-208</strong></td>
<td>HY-12035</td>
<td>AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. IC50 value: 9.3 nM. Target: c-Met in vitro. AMG-208 shows the potent inhibition of kinase c-Met activity with IC50 of 9 nM in a cell-free assay.</td>
</tr>
<tr>
<td><strong>AMG-337</strong></td>
<td>HY-18696</td>
<td>AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of &lt; 5 nM in enzymatic assays.</td>
</tr>
<tr>
<td><strong>Amuvatinib</strong></td>
<td>HY-10206</td>
<td>Amuvatinib (MP470; HPK 56) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, FLT3, c-Met and c-Ret.</td>
</tr>
<tr>
<td><strong>BAY-474</strong></td>
<td>HY-133083</td>
<td>BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 is a structural genomics consortium (SGC) epigenetics probe.</td>
</tr>
<tr>
<td><strong>BMS 777607</strong></td>
<td>HY-12076</td>
<td>BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all...</td>
</tr>
<tr>
<td><strong>BMS-794833</strong></td>
<td>HY-10497</td>
<td>BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50 of 15 and 1.7 nM, respectively.</td>
</tr>
<tr>
<td><strong>Bozitinib</strong></td>
<td>HY-125017</td>
<td>Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.</td>
</tr>
</tbody>
</table>

**IC50** values for relevant compounds:
- **Altiratinib** (DCC-2701): 9 nM
- **AMG-337**: < 5 nM
- **Amuvatinib hydrochloride** (MP470 hydrochloride; HPK 56 hydrochloride): >98%
- **BMS 777607** IC50: 3.9 nM, 1.1 nM, 1.8 nM, 4.3 nM, respectively
- **BMS-794833** IC50: 15 nM, 1.7 nM
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| c-Kit-IN-1        | HY-15240 | Cat No.: HY-15240

C-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC₅₀ of <200 nM.  
Purity: 98.46%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

| c-Met inhibitor 1 | HY-15735 | Cat No.: HY-15735

C-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.  
Purity: 98.72%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

| c-met-IN-1        | HY-101031 | Cat No.: HY-101031

C-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC₅₀ of 1.1 nM, with antitumor activity.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

| c-Met-IN-2        | HY-101773 | Cat No.: HY-101773

C-met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

| Cabozantinib     | HY-13016  | Cat No.: HY-13016

Cabozantinib (XL184; BMS-907351) is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀ of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.  
Purity: 99.85%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

| Capmatinib       | HY-13404  | Cat No.: HY-13404

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM).  
Purity: 99.84%  
Clinical Data: Phase 4  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

| CEP-40783        | HY-100946 | Cat No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.  
Purity: 99.22%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

| Crizotinib       | HY-50878  | Cat No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀ of 20 and 8 nM, respectively.  
Purity: 99.97%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

| Crizotinib hydrochloride | HY-50878A | Cat No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀ of 20 and 8 nM, respectively.  
Purity: 99.86%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

| CSF1R-IN-2       | HY-111787 | Cat No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC₅₀ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.  
Purity: 99.97%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com
Dihexa (PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanyol-Tyr-Ile-Ahx-NH2) Cat. No.: HY-16969

Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (K_d=65 pM) and potentiates its activity at its receptor, c-Met.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

EGFR-IN-8

EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Ensartinib (X-396) Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC_{50}s of <0.4 nM and 0.74 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Ensartinib hydrochloride (X-396 hydrochloride) Cat. No.: HY-103714A

Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC_{50}s of <0.4 nM and 0.74 nM, respectively.

Purity: 98.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Foretinib (XL880; GSK1363089; GSK089; EXEL-2880) Cat. No.: HY-10338

Foretinib is a multi-target tyrosine kinase inhibitor with IC_{50}s of 0.4 nM and 0.9 nM for Met and KDR.

Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Glesatinib hydrochloride (MGCD265 hydrochloride) Cat. No.: HY-19642A

Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.

Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Glumetinib (SCC244) Cat. No.: HY-116000

Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC_{50} of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.

Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golvatinib (E-7050) Cat. No.: HY-13068

Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC_{50}s of 14 and 16 nM, respectively.

Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-3887605

JNJ-3887605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38877618

JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC_{50}s of 2 and 3 nM for wild type and mutant Met, respectively.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
Meleagrin

Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

Merestinib (LY2801653)

Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (K_i = 2 nM) with anti-tumor activities.

- **Purity:** 99.99%
- **Clinical Data:** Phase 2
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride (LY2801653 dihydrochloride)

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (K_i = 2 nM) with anti-tumor activities.

- **Purity:** 99.02%
- **Clinical Data:** Phase 2
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-2461

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.

- **Purity:** 99.92%
- **Clinical Data:** Phase 2
- **Size:** 10 mM x 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

MK-8033 hydrochloride

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

- **Purity:** >98%
- **Clinical Data:** Phase 1
- **Size:** 5 mg, 10 mg, 50 mg

MK-8033

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

- **Purity:** 98.75%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-8033 hydrochloride

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

- **Purity:** >98%
- **Clinical Data:** Phase 1
- **Size:** 5 mg, 10 mg, 50 mg

Ningetinib Tosylate

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50 of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

- **Purity:** >98.0%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MGCD-265 analog

MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.

- **Purity:** 96.53%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MPS-1034

MPS-1034 is a dual inhibitor of AXL and MET with IC50 of 10.3 and 48 nM, respectively.

- **Purity:** >98.0%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
NVP-BVU972

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.

Purity: 97.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-04217903

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 methanesulfonate

PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

S49076

S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.

Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Savolitinib (Volitinib; HMPL-504; AZD-6094)

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively.

Purity: 98.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGX-523

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC50 value: 4 nM Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFRT) tyrosine kinase inhibitors.

Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PHS-665752

PHS-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase (Kd=4 nM; IC50=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.

Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SAR125844

SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SCR-1481B1

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SRI 31215 TFA

SRI 31215 (TFA), a triplex inhibitor of matriptase, hepin and hepatocyte growth factor activator (HGF) with IC50 of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
**SU11274**  
(PKI-SU11274)  
Cat. No.: HY-12014

SU11274 is a selective Met inhibitor with IC\textsubscript{50} of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

Purity: 98.09%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

---

**TAS-115**  
Cat. No.: HY-12423

TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC\textsubscript{50} of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg, 10 mg, 20 mg

---

**TAS-115 mesylate**  
(TAS-115 methanesulfonate)  
Cat. No.: HY-12423A

TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC\textsubscript{50} of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: 99.15%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Tepotinib**  
(EMD-1214063)  
Cat. No.: HY-14721

Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC\textsubscript{50} of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

Purity: 99.87%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Tivantinib**  
(ARQ 197)  
Cat. No.: HY-50686

Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with K\textsubscript{i} of 355 nM.

Purity: 99.39%  
Clinical Data: Phase 3  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

---

**X-376**  
Cat. No.: HY-16590

X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC\textsubscript{50}=0.61 nM). X-376 is a less potent inhibitor of MET (IC\textsubscript{50}=0.69 nM). X-376 displays potent anti-tumor activity.

Purity: 98.36%  
Clinical Data: Phase 3  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Tyrosine kinase inhibitor**  
Cat. No.: HY-10421

A Tyrosine kinase inhibitor.

Purity: 99.36%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg